03211cam a22002774a 450000100090000000300040000900500170001300800410003001000170007102000280008804000180011604200080013405000220014208200250016424500840018926000450027330000320031844000480035050400510039850522320044965000420268170000220272370000220274585600900276785600760285712304436OSt20200219101509.0010208s2001    enka     b    001 0 eng    a  2001017865  a0471822116 (alk. paper)  aDLCcDLCdDLC  apcc00aR853.S7bB49 200100a615.507 24 RED C22100aBiostatistics in clinical trials /ceditors, Carol K. Redmond, Theodore Colton.  aChichester ;aNew York :bWiley,cc2001.  axx, 501 p. :bill. ; 25 cm. 4aThe Wiley reference series in biostatistics  aIncludes bibliographical references and index.  aAdaptive and Dynamic Methods of Treatment Assignment. Antibacterial Agent Trials. Audit and Quality Control. Bayesian Methods. Benefit/Risk Assessment. Binding or Masking. Clinical Significance Versus Statistical Significance. Clinical Trials, Overview. Cluster Randomization. Cochrane Collaboration. Community Intervention Trials. Compliance Assessment. CONSORT. Controlled Clinical Trials. Cooperative Cancer Trials. Cooperative Heart Disease Trials. Cooperative Studies Program, US Department of Veterans Affairs. Cost-effectiveness. Covariate Imbalance, Adjustment for. Crossover Designs. Data and Safety Monitoring. Data and Safety Monitoring Boards. Data Management and Coordination. Drug Approval and Regulation. Drug Interactions. Eligibility and Exclusion Criteria. Equivalence Trials. Ethics. European Federation of Statisticians in the Pharmaceutical Industry (EFPSI). European Organization for Research and Treatment of Cancer (EORTC). Factorial Designs. Fraud. Group-randomization Designs. Guidelines. Historical Controls, Bias From. History, Early Cancer and Heart Disease Trials. History, Overview. Intention-to-Treat Analysis. International Studies of Infarct Survival (ISIS). Medical Ethics and Statistics. Medical Research Council (MRC) Streptomycin Trial. Meta-analysis. Missing Data. Multicenter Trials. Multiple Endpoints. Multiplicity. Noncompliance, Adjustment for. Nonrandomized Trials. NSABP and Advances in the Treatment of Breast Cancer. Number Needed to Treat (NNT). Outcome Measures. Pharmaceutical Industry, Statistics in. Phase I Trials. Phase II Trials. Physicians' Health Study. Postmarketing Surveillance of New Drugs and Assessment of Risk. Preclinical Treatment Evaluation. Prevention Trials. Protocols. QUOROM. Randomization. Randomized Treatment Assignment. Salk Vaccine. Sample Size Determination. Screening Trials. Sequential Methods. Society for Clinical Trials. Software. Statistical Review for Medical Journals. Statistical Review for Medical Journals, Guidelines for Authors. Statisticians in the Pharmaceutical Industry (PSI). Surrogate Endpoints. Textbooks. Time-varying Treatment Effect. Treatment--Covariate Interaction. University Group Diabetes Program (UGDP). Vaccine Studies. 0aClinical trialsxStatistical methods.1 aRedmond, Carol K.1 aColton, Theodore.423Publisher descriptionuhttp://www.loc.gov/catdir/description/wiley034/2001017865.html4 3Table of Contentsuhttp://www.loc.gov/catdir/toc/onix06/2001017865.html